全文获取类型
收费全文 | 110篇 |
免费 | 4篇 |
出版年
2021年 | 1篇 |
2019年 | 1篇 |
2018年 | 1篇 |
2016年 | 1篇 |
2015年 | 5篇 |
2014年 | 6篇 |
2013年 | 7篇 |
2012年 | 5篇 |
2011年 | 12篇 |
2010年 | 4篇 |
2009年 | 5篇 |
2008年 | 4篇 |
2007年 | 4篇 |
2006年 | 3篇 |
2005年 | 5篇 |
2004年 | 6篇 |
2003年 | 5篇 |
2002年 | 3篇 |
2001年 | 5篇 |
2000年 | 5篇 |
1999年 | 2篇 |
1998年 | 1篇 |
1997年 | 3篇 |
1995年 | 2篇 |
1992年 | 3篇 |
1989年 | 3篇 |
1987年 | 1篇 |
1986年 | 2篇 |
1985年 | 3篇 |
1983年 | 2篇 |
1975年 | 1篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1967年 | 1篇 |
排序方式: 共有114条查询结果,搜索用时 281 毫秒
61.
Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases 总被引:9,自引:3,他引:6
Bodolay E Koch AE Kim J Szegedi G Szekanecz Z 《Journal of cellular and molecular medicine》2002,6(3):357-376
Angiogenesis, the formation of new vessels, is important in the pathogenesis of rheumatoid arthritis (RA) and other inflammatory diseases. Chemotactic cytokines termed chemokines mediate the ingress of leukocytes, including neutrophils and monocytes into the inflamed synovium. In this review, authors discuss the role of the most important angiogenic factors and angiogenesis inhibitors, as well as relevant chemokines and chemokine receptors involved in chronic inflammatory rheumatic diseases. RA was chosen as a prototype to discuss these issues, as the majority of studies on the role of angiogenesis and chemokines in inflammatory diseases were carried out in arthritis. However, other systemic inflammatory (autoimmune) diseases including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's syndrome (SS), mixed connective tissue disease (MCTD), polymyositis/dermatomyositis (PM/DM) and systemic vasculites are also discussed in this context. As a number of chemokines may also play a role in neovascularizaton, this issue is also described here. Apart from discussing the pathogenic role of angiogenesis and chemokines, authors also review the regulation of angiogenesis and chemokine production by other inflammatory meditors, as well as the important relevance of neovascularization and chemokines for antirheumatic intervention. 相似文献
62.
Estève E Smida-Rezgui S Sarkozi S Szegedi C Regaya I Chen L Altafaj X Rochat H Allen P Pessah IN Marty I Sabatier JM Jona I De Waard M Ronjat M 《The Journal of biological chemistry》2003,278(39):37822-37831
Maurocalcine (MCa) is a 33 amino acid residue peptide toxin isolated from the scorpion Scorpio maurus palmatus. MCa and mutated analogues were chemically synthesized, and their interaction with the skeletal muscle ryanodine receptor (RyR1) was studied on purified RyR1, sarcoplasmic reticulum (SR) vesicles, and cultured myotubes. MCa strongly potentiates [3H]ryanodine binding on SR vesicles (7-fold at pCa 5) with an apparent EC50 of 12 nm. MCa decreases the sensitivity of [3H]ryanodine binding to inhibitory high Ca2+ concentrations and increases it to the stimulatory low Ca2+ concentrations. In the presence of MCa, purified RyR1 channels show long-lasting openings characterized by a conductance equivalent to 60% of the full conductance. This effect correlates with a global increase in Ca2+ efflux as demonstrated by MCa effects on Ca2+ release from SR vesicles. In addition, we show for the first time that external application of MCa to cultured myotubes produces a cytosolic Ca2+ increase due to Ca2+ release from 4-chloro-m-cresol-sensitive intracellular stores. Using various MCa mutants, we identified a critical role of Arg24 for MCa binding onto RyR1. All of the other MCa mutants are still able to modify [3H]ryanodine binding although with a decreased EC50 and a lower stimulation efficacy. All of the active mutants produce both the appearance of a subconductance state and Ca2+ release from SR vesicles. Overall, these data identify some amino acid residues of MCa that support the effect of this toxin on ryanodine binding, RyR1 biophysical properties, and Ca2+ release from SR. 相似文献
63.
64.
65.
66.
Ribosomal proteins assist the assembly and increase the stability of ribosomal RNA, without requiring ATP for their action. Some ribosomal proteins are also known to have essential functions outside the ribosome, i.e. promiscuity of functions that appears to correlate with their structural disorder. Here we addressed if certain ribosomal proteins with RNA chaperone activity and with a significant level of disorder also have protein-chaperone activity in vitro. Four proteins of the large subunit of Escherichia coli ribosome, L15, L16, L18 and L19 have been tested in three chaperone assays, in which all of them exhibited potent chaperone activity, commensurable with that of heat shock protein 90 kDa. These observations highlight possible novel aspects of the promiscuous functions of ribosomal proteins outside of the ribosome. 相似文献
67.
68.
Eva Zold Peter Szodoray Janos Gaal János Kappelmayer Laszlo Csathy Edit Gyimesi Margit Zeher Gyula Szegedi Edit Bodolay 《Arthritis research & therapy》2008,10(5):1-8
Osteoporosis and disorders of bone fragility are highly heritable, but despite much effort the identities of few of the genes involved has been established. Recent developments in genetics such as genome-wide association studies are revolutionizing research in this field, and it is likely that further contributions will be made through application of next-generation sequencing technologies, analysis of copy number variation polymorphisms, and high-throughput mouse mutagenesis programs. This article outlines what we know about osteoporosis genetics to date and the probable future directions of research in this field. 相似文献
69.
Objective To investigate the efficacy of hypericum extract WS 5570 (St John''s wort) compared with paroxetine in patients with moderate to severe major depression.Design Randomised double blind, double dummy, reference controlled, multicentre non-inferiority trial.Setting 21 psychiatric primary care practices in Germany.Participants 251 adult outpatients with acute major depression with total score ≥ 22 on the 17 item Hamilton depression scale.Interventions 900 mg/day hypericum extract WS 5570 three times a day or 20 mg paroxetine once a day for six weeks. In initial non-responders doses were increased to 1800 mg/day hypericum or 40 mg/day paroxetine after two weeks.Main outcome measures Change in score on Hamilton depression scale from baseline to day 42 (primary outcome). Secondary measures were change in scores on Montgomery-Åsberg depression rating scale, clinical global impressions, and Beck depression inventory.Results The Hamilton depression total score decreased by mean 14.4 (SD 8.8) points, corresponding to 56.6% (SD 34.3%) of the baseline value, in the hypericum group and by 11.4 (SD 8.6) points (44.8% (SD 33.5%) of baseline value) in the paroxetine group (intention to treat analysis; similar results were observed in the per protocol analysis). The intention to treat analysis (lower one sided 97.5% confidence limit 1.5 points for the difference hypericum minus paroxetine) and the per protocol analysis (lower confidence limit 0.7 points) showed non-inferiority of hypericum and statistical superiority over paroxetine. The lower limits in both cases exceeded the pre-specified non-inferiority margin of -2.5 points and the superiority margin of 0. The incidence of adverse events was 0.035 and 0.060 events per day of exposure for hypericum and paroxetine, respectively.Conclusions In the treatment of moderate to severe major depression, hypericum extract WS 5570 is at least as effective as paroxetine and is better tolerated. 相似文献
70.
A. Galambos A. Zok A. Kuczmog R. Oláh P. Putnoky W. Ream E. Szegedi 《Plant cell reports》2013,32(11):1751-1757